Budesonide Rectal Foam and Tofacitinib Extended-Release Tablets
Determining the interaction of Budesonide Rectal Foam and Tofacitinib Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using tofacitinib together with budesonide may increase the risk of serious and potentially fatal infections. In some cases, combining medications that affect the bone marrow or immune system can also increase the risk of various types of cancer over time. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants. Epstein Barr virus-associated posttransplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive agents (basiliximab, high-dose corticosteroids, and mycophenolic acid) relative to cyclosporine plus the same induction regimen (2.3% vs. 0%).
MANAGEMENT: Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.
- "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: budesonide
Brand name: Entocort EC, Uceris, Pulmicort Flexhaler, Pulmicort Respules
Synonyms: Budesonide, Budesonide (Oral Inhalation)
Generic Name: tofacitinib
Brand name: Xeljanz, Xeljanz XR
Synonyms: Tofacitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Budesonide Rectal Foam-Tofacitinib Tablets
- Budesonide Rectal Foam-Tofranil
- Budesonide Rectal Foam-Tofranil injection
- Budesonide Rectal Foam-Tofranil-PM
- Budesonide Rectal Foam-Tol-Tab
- Budesonide Rectal Foam-Tolazamide
- Tofacitinib Extended-Release Tablets-Bufen
- Tofacitinib Extended-Release Tablets-Buffered Salt
- Tofacitinib Extended-Release Tablets-Bumetanide
- Tofacitinib Extended-Release Tablets-Bumetanide Injection
- Tofacitinib Extended-Release Tablets-Bumetanide oral/injection
- Tofacitinib Extended-Release Tablets-Bumetanide Tablets